Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment

INTRODUCTION: There is a pressing need to develop novel drugs for treating patients with chronic hepatitis B (CHB), as commercially available antiviral drugs are endowed with safety and efficacy concerns. METHODS: A phase III clinical trial was conducted with a therapeutic vaccine containing two ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Mahtab, Mamun, Akbar, Sheikh Mohammad Fazle, Aguilar, Julio Cesar, Yoshida, Osamu, Khan, Sakirul, Gerardo, Guillen Nieto, Hiasa, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945514/
https://www.ncbi.nlm.nih.gov/pubmed/36844221
http://dx.doi.org/10.3389/fmed.2023.1032531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945514/
https://www.ncbi.nlm.nih.gov/pubmed/36844221
http://dx.doi.org/10.3389/fmed.2023.1032531

Ejemplares similares